DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
20 hedge funds and large institutions have $10.6M invested in DMK Pharmaceuticals Corporation Common Stock in 2014 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
54% more funds holding
Funds holding: 13 → 20 (+7)
18% less capital invested
Capital invested by funds: $12.9M → $10.6M (-$2.29M)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$427K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$153K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$137K |
| 4 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
+$130K |
| 5 |
Jane Street
New York
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.24M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$726K |
| 3 |
SC
Sophrosyne Capital
New York
|
-$267K |
| 4 |
EEG
E.E. Geduld
|
-$97.1K |
| 5 |
Morgan Stanley
New York
|
-$15.4K |
DMK Hedge Fund Activity: Q1 2014 in Review
20 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2014, worth a combined $10.6M — down 18% from $12.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new DMK positions and 3 closed out — a net gain of 7 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $427K. The largest seller was Sabby Management, cutting an estimated $2.24M.
- 20 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2014, up from 13 in Q4 2013.
- Funds reported $10.6M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2014, down 18% quarter-over-quarter.
- 10 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2014 and 3 closed out, a net change of +7 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2014 was Goldman Sachs, an estimated $427K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2014 was Sabby Management, an estimated $2.24M sold.
Based on aggregated 13F filings for Q1 2014.